{"filings":[{"id":1056356,"accession_number":"0001193125-26-271055","cik":1434316,"company_name":"FATE THERAPEUTICS INC","ticker":"FATE","form_type":"8-K","filed_at":"2026-06-15T20:02:48+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Fate Therapeutics shareholders approve 7M share increase to stock plan at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved 3rd A&R 2022 Stock Plan adding 7M shares; votes: 46.6M for, 14.3M against (26.1M broker non-votes).","Directors Epstein, Jooss, Hamill re-elected with 59.3M, 59.7M, 60.9M votes for, respectively.","Ernst & Young ratified as independent auditor for FY2026; 86.6M for, 0.3M against.","Non-binding advisory vote on executive compensation passed with 59.2M for, 1.8M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":292435334.5356962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":862156,"accession_number":"0001193125-26-257558","cik":1434316,"company_name":"FATE THERAPEUTICS INC","ticker":"FATE","form_type":"8-K","filed_at":"2026-06-04T20:37:03+00:00","items":["8.01","9.01"],"status":"ready","headline":"Fate updates corporate presentation for EULAR 2026; no specific new data in exhibit","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company filed an updated corporate presentation for use at the EULAR 2026 Congress on June 4, 2026.","Presentation focuses on cell therapies for autoimmune diseases and cancer; ticker FATE listed on Nasdaq.","No financial results, pipeline updates, or concrete milestones disclosed in the excerpted exhibit.","Event is a routine update of investor materials; materiality is limited given lack of specific numbers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":292435334.5356962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":50641,"accession_number":"0001193125-26-220691","cik":1434316,"company_name":"FATE THERAPEUTICS INC","ticker":"FATE","form_type":"8-K","filed_at":"2026-05-13T12:32:07+00:00","items":["2.02","9.01"],"status":"ready","headline":"Fate Therapeutics Q1 2026: $174.8M cash, $1.3M revenue; FT819 lupus trial on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents, and investments of $174.8M as of March 31, 2026; operating runway extended into 2028.","Total revenue $1.3M from Ono Pharmaceutical collaboration; total operating expenses $34.3M (R&D $24.7M, G&A $9.6M, including $3.9M stock-based comp).","RECLAIM-LN Phase 2 potentially registrational trial of FT819 for lupus nephritis on track to initiate in H2 2026; approximately 53 patients planned.","FT819 selected into FDA CDRP program for enhanced CMC engagement; also has RMAT designation for SLE.","FT839 IND planned H2 2026 for autoimmune diseases; FT836 Phase 1 enrolling solid tumor patients with no ICANS/GvHD/CRS or DLTs observed."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":1299000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":292435334.5356962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103996,"accession_number":"0001193125-26-073689","cik":1434316,"company_name":"FATE THERAPEUTICS INC","ticker":"FATE","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Fate Therapeutics Q4: cash $205M, OpEx down 30%, FT819 outpatient treatment milestone","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and investments $205.1M as of Dec 31, 2025; operating runway through year-end 2027.","Q4 revenue $1.4M from Ono collaboration; total operating expenses $36.1M (R&D $25.4M, G&A $10.7M).","FT819 off-the-shelf CAR T: 15 SLE, 4 SSc, 1 IIM patients treated; outpatient same-day discharge achieved.","FT836 (Sword & Shield) in CRC: first patient shows >50% CEA reduction and tumor shrinkage at DL1 without conditioning chemo.","Operating expenses reduced 30% in 2025 vs 2024; common shares 115.4M, pre-funded warrants 3.9M, preferred 2.8M."],"consensus_eps_estimate":-0.2751,"consensus_eps_actual":-1.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":6646000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":292435334.5356962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120270,"accession_number":"0001193125-25-279091","cik":1434316,"company_name":"FATE THERAPEUTICS INC","ticker":"FATE","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Fate Therapeutics Q3 cash $225.7M; UK/EU approval for FT819; first SSc patient treated","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents & investments $225.7M; projected runway through year-end 2027.","Total revenue $1.7M from Ono collaboration; operating expenses $36.5M incl. $4.9M SBC.","Received UK MHRA and EU EMA authorization to activate ex-US sites for FT819 in autoimmune disease.","First systemic sclerosis patient treated in Phase 1 with fludarabine-free conditioning; no notable AEs.","First patient (stage IV CRC) treated with FT836 MICA/B-targeted CAR T with no conditioning chemotherapy."],"consensus_eps_estimate":-0.2969,"consensus_eps_actual":-0.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":5277000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":292435334.5356962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120269,"accession_number":"0001193125-25-250674","cik":1434316,"company_name":"FATE THERAPEUTICS INC","ticker":"FATE","form_type":"8-K","filed_at":"2025-10-27T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"FT819 SLE data: 10 patients show durable responses; expansion cohorts; pivotal study planned 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["10 SLE patients treated; 2 with lupus nephritis achieved CRR at 6 months; 1 in DORIS at 15 months.","No dose-limiting toxicities, low-grade CRS, no ICANS or GvHD; supports same-day discharge plans.","Initiated dose-expansion cohorts in AAV, IIM, and SSc; engaging FDA for registrational study design with pivotal study goal in 2026.","Approximately 600 cryopreserved FT819 bags in inventory available for patient treatment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":292435334.5356962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120268,"accession_number":"0001193125-25-238989","cik":1434316,"company_name":"FATE THERAPEUTICS INC","ticker":"FATE","form_type":"8-K","filed_at":"2025-10-14T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Fate Therapeutics appoints Kamal Adawi as CFO, board resignations reduce size from 10 to 8","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kamal Adawi appointed CFO effective Oct 20, 2025; base salary $495k, target bonus 40%.","Adawi receives 375k stock option and 75k RSUs as inducement equity grants, vesting over 4 years.","Board members John Mendlein and Neelufar Mozaffarian resigned voluntarily effective Oct 13, 2025.","Board size decreased from 10 to 8 directors following resignations.","CFO role focused on supporting registrational path for FT819 in SLE and pipeline progress."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":292435334.5356962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136857,"accession_number":"0001193125-25-178947","cik":1434316,"company_name":"FATE THERAPEUTICS INC","ticker":"FATE","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","2.05","9.01"],"status":"ready","headline":"Fate Therapeutics Q2 2025 cash $248.9M; 12% workforce cut; FT819 lupus response durable","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2025 cash, cash equivalents & investments $248.9M; total revenue $1.9M from Ono collaboration; operating expenses $38.9M.","Board approved 12% workforce reduction; expects severance charges of $0.9M–$1.2M in Q3 2025; cash runway extended through YE 2027.","FT819 SLE/LN: First patient on fludarabine-free conditioning achieved DORIS at 12-month follow-up; first extrarenal SLE patient without conditioning achieved LLDAS at 3 & 6 months.","FDA allowed IND for FT836 MICA/B-targeted CAR T-cell program; Phase 1 to test without conditioning chemotherapy in solid tumors.","Ono collaboration extended for second solid tumor CAR T candidate through at least June 2026."],"consensus_eps_estimate":-0.3493,"consensus_eps_actual":-0.61,"consensus_revenue_estimate":null,"consensus_revenue_actual":3536000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":292435334.5356962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154089,"accession_number":"0001193125-25-142037","cik":1434316,"company_name":"FATE THERAPEUTICS INC","ticker":"FATE","form_type":"8-K/A","filed_at":"2025-06-17T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Fate Therapeutics board sets annual say-on-pay votes after stockholder advisory approval","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders approved advisory vote on executive compensation every one year.","Board determined to hold non-binding say-on-pay votes annually.","Next frequency vote required no later than 2031 annual meeting.","No other changes from original May 30, 2025 8-K reported."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":292435334.5356962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154091,"accession_number":"0001193125-25-132301","cik":1434316,"company_name":"FATE THERAPEUTICS INC","ticker":"FATE","form_type":"8-K","filed_at":"2025-05-30T23:59:59+00:00","items":["5.02","5.07","5.03","7.01","9.01"],"status":"ready","headline":"Fate Therapeutics appoints Matthew Abernethy to board; shareholders boost authorized shares to 350M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Matthew Abernethy, CFO of Neurocrine Biosciences, appointed Class III director; Timothy P. Coughlin steps down.","Stockholders approved increase in authorized common shares from 250M to 350M, effective May 29, 2025.","Second amendment to 2022 stock plan approved, adding 7M shares to the reserve.","Dr. Shefali Agarwal and Dr. Bahram Valamehr re-elected Class III directors; E&Y ratified as auditor.","Non-binding say-on-pay passed with ~68.9M for (92.4% of votes cast); frequency set at 1 year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":292435334.5356962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154090,"accession_number":"0000950170-25-070280","cik":1434316,"company_name":"FATE THERAPEUTICS INC","ticker":"FATE","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Fate Therapeutics Q1 cash $272.7M; FT819 gets RMAT designation for SLE","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash, equivalents, and investments $272.7M as of March 31, 2025; projected runway through 1H27.","FT819 granted RMAT designation by FDA for moderate-to-severe SLE; new data at EULAR June 11.","Phase 1 study expanded to include AAV, IIM, SSc autoimmune disease cohorts; enrollment ongoing.","Revenue $1.6M from Ono collaboration; total operating expenses $42.9M (R&D $29.1M, G&A $13.8M).","Common shares outstanding 114.6M; preferred shares (convertible 5:1) 2.8M; pre-funded warrants 3.9M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":292435334.5356962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172708,"accession_number":"0000950170-25-033507","cik":1434316,"company_name":"FATE THERAPEUTICS INC","ticker":"FATE","form_type":"8-K","filed_at":"2025-03-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Fate Therapeutics: $306.7M cash runway through YE26; FT819 Phase 1 dose expansion in SLE underway","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and investments of $306.7M; projected operating runway through year-end 2026.","Initiated Phase 1 dose expansion of FT819 CAR T in SLE with flu-free conditioning (bendamustine or cyclophosphamide alone).","First SLE patient treated with FT819 as add-on to maintenance therapy without conditioning; no DLTs, CRS, or ICANS.","Completed Type D meeting with FDA to allow FT819 expansion into AAV, IIM, SSc; multi-dose and re-treatment permitted.","Q4 total operating expenses $63.6M, including $14.7M non-cash impairment; revenue $1.9M from Ono collaboration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":292435334.5356962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172707,"accession_number":"0001193125-25-002153","cik":1434316,"company_name":"FATE THERAPEUTICS INC","ticker":"FATE","form_type":"8-K","filed_at":"2025-01-06T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Fate Therapeutics CEO J. Scott Wolchko retires; Bahram Valamehr appointed successor; advisory agreement signed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["J. Scott Wolchko retired as President, CEO, and CFO effective Dec 31, 2024; resignation not due to any policy disagreement.","Bahram Valamehr, Ph.D., MBA succeeded as President, CEO, and subsidiary roles effective Jan 1, 2025.","Wolchko entered 12-month advisory agreement with $56,250 monthly cash compensation and continued equity vesting through Dec 31, 2025.","Wolchko's vested options may be exercised until Dec 31, 2026; equity awards accelerate if agreement terminated early by company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":292435334.5356962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189722,"accession_number":"0001193125-24-268003","cik":1434316,"company_name":"FATE THERAPEUTICS INC","ticker":"FATE","form_type":"8-K","filed_at":"2024-11-29T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Fate Therapeutics CEO Scott Wolchko to retire Dec 31; succeeded by Bob Valamehr","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Wolchko resigned from board Nov 27, 2024; will retire as President & CEO effective Dec 31, 2024.","Valamehr, currently President of R&D, becomes President & CEO Jan 1, 2025; also named director.","Wolchko to remain a strategic advisor after retirement; resignation not due to any disagreement.","Valamehr has led iPSC platform development ~15 years; oversaw 13 IND applications and pipeline.","FT819 SLE trial: first patient achieved drug-free remission after single dose; no dose-limiting toxicities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":292435334.5356962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189721,"accession_number":"0000950170-24-125307","cik":1434316,"company_name":"FATE THERAPEUTICS INC","ticker":"FATE","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Fate Therapeutics Q3 rev $3.1M, cash $330.5M; FT819/FT522/FT825 clinical progress","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue of $3.1M from Ono collaboration; total op expense $55.5M incl $11.8M stock comp.","Cash, equivalents & investments $330.5M; projected operating runway through end of 2026.","FT819 Phase 1 SLE: 3 patients dosed with fludarabine-free conditioning; no DLTs/CRS/ICANS/GvHD; data at ACR and ASH.","FT522 IND allowed for B cell-mediated autoimmune basket study; initial BCL clinical data at ACR Convergence.","FT825/ONO-8250 initial solid tumor data: safety profile favorable, CAR T expansion with activated phenotype at 100M dose."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":11771000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":292435334.5356962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206229,"accession_number":"0001193125-24-211130","cik":1434316,"company_name":"FATE THERAPEUTICS INC","ticker":"FATE","form_type":"8-K","filed_at":"2024-08-30T23:59:59+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"Fate Therapeutics adopts amended indemnification agreements for directors and officers","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved amended form of indemnification agreement effective August 26, 2024.","Revised change-of-control definition and added coverage of separate counsel expenses in change of control.","Advancement of defense expenses clarified to be irrespective of insurance coverage.","Includes express presumption of good faith in favor of Indemnitee (burden on challenger).","Indemnitee may seek specific performance without showing irreparable harm."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":292435334.5356962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206228,"accession_number":"0000950170-24-096177","cik":1434316,"company_name":"FATE THERAPEUTICS INC","ticker":"FATE","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Fate Therapeutics Q2 2024: Cash $352M; FT819 SLE study adds Cy; FT522 first patient without conditioning","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents & investments $352.0M; projected operating runway through YE26.","Revenue $6.8M (incl. $5M milestone from Ono); GAAP operating expenses $51.9M (R&D $34.6M, G&A $17.3M).","FT819 Phase 1 SLE study: first patient (lupus nephritis) dosed; protocol amended to include single-agent cyclophosphamide; no Grade≥3 AEs, no CRS/ICANS/GvHD.","FT825/ONO-8250 Phase 1 solid tumor study: three patients treated as monotherapy; combo dosing with mAb expected 3Q24.","FT522 Phase 1 BCL study: first patient treated without conditioning chemotherapy at 300M cells/dose; IND for autoimmune basket study planned 3Q24."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.79,"consensus_revenue_estimate":null,"consensus_revenue_actual":8697000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":292435334.5356962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206227,"accession_number":"0001193125-24-189911","cik":1434316,"company_name":"FATE THERAPEUTICS INC","ticker":"FATE","form_type":"8-K","filed_at":"2024-07-31T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Fate Therapeutics appoints Dr. Neely Mozaffarian to Board, expanding to 10 members","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Mozaffarian appointed effective July 29, 2024, as Class II director and member of NCG and Science & Technology committees.","Board increased from 9 to 10 directors; Mozaffarian fills newly created vacancy.","Received option to purchase 80,000 shares at July 29 closing price, vesting monthly over 36 months.","Mozaffarian is CMO at Atomwise with over 20 years immunology/autoimmunity R&D leadership.","Appointment adds expertise in autoimmune disease and cell therapy development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":292435334.5356962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223290,"accession_number":"0001193125-24-158374","cik":1434316,"company_name":"FATE THERAPEUTICS INC","ticker":"FATE","form_type":"8-K","filed_at":"2024-06-10T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Fate Therapeutics stockholders approve charter amendment to exculpate officers","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Certificate of Amendment to Amended and Restated Certificate of Incorporation approved by stockholders at Annual Meeting on June 7, 2024.","Amendment allows exculpation of certain officers, limiting personal liability for breaches of fiduciary duty.","Effective upon filing with Delaware Secretary of State on June 7, 2024.","Board recommended the amendment; stockholders voted to approve."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":292435334.5356962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223289,"accession_number":"0001193125-24-157554","cik":1434316,"company_name":"FATE THERAPEUTICS INC","ticker":"FATE","form_type":"8-K","filed_at":"2024-06-07T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"CEO J. Scott Wolchko assumes CFO role after Edward Dulac's resignation; stock plan expanded","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Edward Dulac resigned effective June 14, 2024; CEO J. Scott Wolchko appointed as CFO and principal financial/accounting officer.","Wolchko previously served as CFO from company inception until August 2020; no change to his compensation.","Stockholders approved amendment to 2022 Stock Option Plan, increasing available shares by 8,000,000 to 17,500,000 total.","Other proposals passed: election of three Class II directors, ratification of EY, say-on-pay, officer exculpation amendment.","Broker non-votes were ~6.7M on most items; say-on-pay passed with ~65.4M for vs 25.6M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":292435334.5356962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223288,"accession_number":"0001193125-24-151963","cik":1434316,"company_name":"FATE THERAPEUTICS INC","ticker":"FATE","form_type":"8-K","filed_at":"2024-05-31T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CFO Edward J. Dulac III resigns; CEO J. Scott Wolchko to assume CFO role effective June 14, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Edward J. Dulac III resigned as CFO voluntarily, effective June 14, 2024; no disagreement with the company.","CEO J. Scott Wolchko will succeed Dulac as CFO and principal financial/accounting officer immediately after resignation.","Wolchko previously served as CFO from company inception until August 2020."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":292435334.5356962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223287,"accession_number":"0001193125-24-134840","cik":1434316,"company_name":"FATE THERAPEUTICS INC","ticker":"FATE","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Fate Therapeutics treats first SLE patient with FT819; advances autoimmune pipeline","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First SLE patient dosed in Phase 1 autoimmunity study of FT819 (CD19 CAR T); discharged after 3 days with no notable AEs.","FT819 translational data: rapid deep B-cell depletion, tissue trafficking, plasma cell depletion; fludarabine not required in some cases.","FT522 (CAR NK) initial observations: rapid sustained B-cell depletion and enhanced persistence vs FT596 in first two BCL patients.","Company completed dose escalation in FT819 BCM study; will focus FT819 solely on autoimmunity; FT522 IND for autoimmune diseases expected mid-2024.","FT819 safety in BCM study: no DLTs, ICANS, or GvHD; low-grade CRS in 14% of patients; no study discontinuations or deaths."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":292435334.5356962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223286,"accession_number":"0000950170-24-056852","cik":1434316,"company_name":"FATE THERAPEUTICS INC","ticker":"FATE","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Fate Therapeutics Q1 revenue $1.9M; $391M cash; advances FT819 in SLE, halts FT576 expansion","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents & investments: $391.1M as of March 31, 2024, including ~$80M offering and ~$20M private placement.","Q1 revenue $1.9M (collaboration with Ono); GAAP operating expenses $53.0M (R&D $32.1M, G&A $20.9M, incl $11M stock comp).","First SLE patient treated with FT819 CAR T; dose escalation completed in BCM; FT819 development to focus exclusively on autoimmunity.","FT522 enrollment opened without conditioning chemotherapy in Phase 1 BCL; IND for autoimmunity planned mid-2024.","FT576 dose escalation completed in multiple myeloma; company will not advance to Phase 1 dose expansion; evaluating next-gen BCMA candidates."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":1925000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":292435334.5356962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242766,"accession_number":"0001193125-24-072871","cik":1434316,"company_name":"FATE THERAPEUTICS INC","ticker":"FATE","form_type":"8-K","filed_at":"2024-03-21T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Fate Therapeutics prices $100M equity offering and private placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Underwritten offering of 14,545,454 shares at $5.50/share; net proceeds ~$74.7M.","Concurrent private placement of pre-funded warrants to Redmile for ~$20M at $5.499/warrant.","Total gross proceeds ~$100M; expected close March 21, 2024.","Net proceeds to fund clinical trials, manufacturing, and working capital.","BofA Securities, Jefferies, Leerink Partners act as joint bookrunners."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":292435334.5356962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242765,"accession_number":"0000950170-24-020123","cik":1434316,"company_name":"FATE THERAPEUTICS INC","ticker":"FATE","form_type":"8-K","filed_at":"2024-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Fate Therapeutics Q4 revenue $1.7M, cash $316M; FT522 first patient dosed, FT825 study initiated","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and investments $316.2M at Dec 31, 2023; Q4 GAAP operating expenses $49.8M (R&D $31.8M, G&A $17.9M).","Revenue $1.7M from Ono collaboration preclinical activities; no product revenue.","FT522 (CAR NK) first patient treated; Phase 1 includes ADR technology, regimen with/without chemo conditioning.","FT825/ONO-8250 (CAR T) Phase 1 started for solid tumors; HER2-targeted with novel synthetic controls.","CIRM awarded $7.9M grant for FT819 Phase 1 SLE study; study start-up at multiple U.S. sites."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.64,"consensus_revenue_estimate":null,"consensus_revenue_actual":63533000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":292435334.5356962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260147,"accession_number":"0001193125-23-273633","cik":1434316,"company_name":"FATE THERAPEUTICS INC","ticker":"FATE","form_type":"8-K","filed_at":"2023-11-08T23:59:59+00:00","items":["1.01","1.02","9.01"],"status":"ready","headline":"Fate Therapeutics files $300M shelf, enters $100M ATM with Jefferies; terminates prior agreement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed S-3 shelf registration for up to $300M of common, preferred, debt, warrants, and units.","Entered ATM offering agreement with Jefferies for up to $100M of common stock at market prices.","Jefferies will receive a 3% commission on gross proceeds from any ATM sales.","Prior ATM facility dated Nov 4, 2021 terminated and replaced by the new agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":292435334.5356962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260146,"accession_number":"0000950170-23-061077","cik":1434316,"company_name":"FATE THERAPEUTICS INC","ticker":"FATE","form_type":"8-K","filed_at":"2023-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Fate Therapeutics Q3 2023: $350M cash, multiple IND clearances, FT522 enrollment started","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents & investments $349.7M as of Sept 30, 2023; runway into 2H25.","Revenue $1.9M from ONO collaboration; GAAP operating expenses $53.2M (R&D $34.3M, G&A $18.9M).","FT522 Phase 1 open for enrollment in B-cell lymphoma; 3-dose cohort at 300M cells per dose.","IND cleared for FT825/ONO-8250 CAR T targeting HER2 in solid tumors; Phase 1 start-up ongoing.","IND cleared for FT819 CAR T in systemic lupus erythematosus; Phase 1 design includes single dose with preconditioning."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":61857000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":292435334.5356962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277439,"accession_number":"0001193125-23-227749","cik":1434316,"company_name":"FATE THERAPEUTICS INC","ticker":"FATE","form_type":"8-K","filed_at":"2023-09-01T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Fate Therapeutics loses summary judgment in patent case against Shoreline; plans appeal","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Court granted Shoreline's summary judgment of non-infringement on Whitehead Patents covering iPSC technology.","Fate strongly disagrees with ruling and will consider appeal; validity and enforceability of patents unaffected.","State case for breach of contract and fraud against Shoreline ongoing; trial set for January 2024.","Shoreline argued it purchases iPSC lines from third parties, not directly infringing Fate's patents."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":292435334.5356962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277438,"accession_number":"0000950170-23-039783","cik":1434316,"company_name":"FATE THERAPEUTICS INC","ticker":"FATE","form_type":"8-K","filed_at":"2023-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Fate Therapeutics Q2 2023: cash $385M, FT522 Phase 1 start-up, FT825 IND planned 2H23","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash position $385.2M as of June 30, 2023; runway into 2H25.","Q2 2023 revenue $0.9M from ONO collaboration; GAAP op ex $63.5M incl $12.9M stock comp.","Phase 1 start-up for FT522 ADR-armed CAR NK program; IND allowed May 2023.","IND submission planned 2H23 for FT825/ONO-8250 HER2-targeted CAR T program under ONO collaboration.","FT576 BCMA-targeted CAR NK and FT819 CD19-targeted CAR T programs enrolling patients in dose escalation."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":59913000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":292435334.5356962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295354,"accession_number":"0000950170-23-027262","cik":1434316,"company_name":"FATE THERAPEUTICS INC","ticker":"FATE","form_type":"8-K","filed_at":"2023-06-09T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Fate Therapeutics reports 2023 annual meeting voting results","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Class I directors Epstein, Mendlein, Jooss with >65.8M 'for' votes each; 10.2M broker non-votes.","Ratified Ernst & Young as auditor for FY2023: 85.5M for, 0.2M against, 1.2M abstentions.","Approved non-binding advisory vote on executive compensation: 73.7M for, 3.0M against, 0.1M abstentions.","Total shares present at meeting: 86.9M of 98.2M outstanding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":292435334.5356962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295353,"accession_number":"0000950170-23-027007","cik":1434316,"company_name":"FATE THERAPEUTICS INC","ticker":"FATE","form_type":"8-K","filed_at":"2023-06-08T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Fate Therapeutics CMO Dr. Wayne Chu resigns effective July 14, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Yu-Waye (Wayne) Chu, Chief Medical Officer, resigns to pursue another opportunity.","Resignation effective July 14, 2023; no disagreement with company operations or policies.","No replacement named; CEO J. Scott Wolchko signed the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":292435334.5356962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295352,"accession_number":"0000950170-23-026747","cik":1434316,"company_name":"FATE THERAPEUTICS INC","ticker":"FATE","form_type":"8-K","filed_at":"2023-06-07T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Fate Therapeutics announces FDA clearance of FT522 IND for Phase 1 trial in B-cell lymphoma","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA allowed IND for FT522, an induced pluripotent stem cell-derived CAR NK-cell product candidate.","Phase 1 dose-escalating trial will assess FT522 plus CD20-targeted mAb in relapsed/refractory B-cell lymphoma.","Two regimens: with or without conditioning chemotherapy; starting dose 300M cells per dose in three-dose schedule.","Regimen A enrollment to begin first; Regimen B will start after DLT clearance at initial dose level.","Company presented update at 2023 Jefferies Healthcare Conference on June 7, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":292435334.5356962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295351,"accession_number":"0000950170-23-017157","cik":1434316,"company_name":"FATE THERAPEUTICS INC","ticker":"FATE","form_type":"8-K","filed_at":"2023-05-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Fate Therapeutics Q1 revenue $59M via Janssen termination; cuts workforce, runway to 2H25","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 GAAP operating expenses $87.6M including $12.9M severance; revenue includes $52.3M from Janssen termination.","Cash, cash equivalents & investments $412.8M; with $13.5M receivables, expects >$300M at year-end 2023.","Discontinued Janssen collaboration, withdrew IND; terminated NK programs FT516, FT596, FT538, FT536.","Workforce reduced to ~220 employees; 2023 GAAP op-ex guidance $265M-$285M.","FT576 enrolling multi-dose cohorts; FT522 IND submitted; FT819 advancing; HER2 IND planned 2H23."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":58980000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":292435334.5356962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295350,"accession_number":"0000950170-23-013471","cik":1434316,"company_name":"FATE THERAPEUTICS INC","ticker":"FATE","form_type":"8-K","filed_at":"2023-04-19T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"Fate Therapeutics amends beneficial ownership limitation on Class A Convertible Preferred Stock to 14.99%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed Certificate of Amendment to Class A Convertible Preferred Stock Certificate of Designation on April 13, 2023.","Beneficial Ownership Limitation set at 14.99% of outstanding common shares following conversion.","Amendment modifies definition in Section 6(c) of the Certificate of Designation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":292435334.5356962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315897,"accession_number":"0000950170-23-005063","cik":1434316,"company_name":"FATE THERAPEUTICS INC","ticker":"FATE","form_type":"8-K","filed_at":"2023-02-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Fate Therapeutics reports Q4 revenue $44.4M; ends Janssen deal, cuts workforce to ~220","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash and investments $441.2M plus $38.5M receivables; total ~$475M as of Dec 31, 2022.","Q4 2022 revenue $44.4M from collaborations; R&D expense $87.2M, G&A $21.6M.","Janssen collaboration terminated effective Apr 3, 2023; all programs discontinued.","Restructuring reduces headcount to ~220; expects $12-16M severance charges in Q1 2023.","IND planned mid-2023 for FT522 in B-cell lymphoma; FT825/ONO-8250 IND expected in 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":292435334.5356962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315896,"accession_number":"0001193125-23-002504","cik":1434316,"company_name":"FATE THERAPEUTICS INC","ticker":"FATE","form_type":"8-K","filed_at":"2023-01-05T23:59:59+00:00","items":["1.02","2.05","5.02","8.01","9.01"],"status":"ready","headline":"Fate Therapeutics ends Janssen deal, cuts workforce to 220, discontinues four NK programs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Janssen collaboration terminated effective April 3, 2023; all activities wound down in Q1 2023.","Workforce reduced to ~220 employees; expects $15M severance charges in Q1 2023.","Discontinues FT516, FT596, FT538, FT536 NK programs; focuses on second-gen CD19 CAR NK, FT576, FT819, FT825/ONO-8250.","CTO Mark Plavsic to depart March 6, 2023; receives 9 months base salary and equity acceleration.","Unrestricted cash, equivalents, and receivables ~$475M at year-end 2022; cash runway extended through 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":292435334.5356962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":334225,"accession_number":"0000950170-22-022488","cik":1434316,"company_name":"FATE THERAPEUTICS INC","ticker":"FATE","form_type":"8-K","filed_at":"2022-11-07T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Ono exercises option to Fate's HER2 CAR T-cell candidate; Fate to receive $12.5M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Ono exercised option to FT825/ONO-8250, triggering $12.5M option exercise fee to Fate.","Fate and Ono to jointly develop and commercialize the candidate in the U.S. and Europe; Ono has exclusive rights elsewhere.","Preclinical data showed broad, potent anti-tumor activity against HER2-low tumor cells.","Fate eligible for additional clinical, regulatory, and commercial milestones plus tiered royalties on sales outside US/EU.","Collaboration expanded to include a second solid tumor antigen program for preclinical development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":292435334.5356962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":334224,"accession_number":"0000950170-22-021834","cik":1434316,"company_name":"FATE THERAPEUTICS INC","ticker":"FATE","form_type":"8-K","filed_at":"2022-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Fate Therapeutics Q3 2022: Cash $519M, $15M revenue; FDA positive feedback on FT516 RMAT; pipeline progress","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and investments $519.1M; Q3 revenue $15.0M from Janssen/ONO collaborations; R&D expense $79.8M.","Positive FDA feedback under FT516 RMAT for clonal master iPSC bank and potential registrational study design; CMC meeting set for December.","Enrollment ongoing for FT596+R three-dose escalation at 1.8B cells/dose for R/R BCL; activating community sites for FT596+R-CHOP in newly-diagnosed aggressive BCL.","Janssen exercised option for second iPSC-derived CAR NK product targeting undisclosed hematologic malignancy antigen; FT555 (GPRC5D) IND candidate for MM to be presented at ASH.","14 abstracts selected for ASH and 12 for SITC, including interim Phase 1 data for FT576 (MM), FT819 (BCL), FT536/FT538 (solid tumors)."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":51944000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":292435334.5356962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":351645,"accession_number":"0000950170-22-014223","cik":1434316,"company_name":"FATE THERAPEUTICS INC","ticker":"FATE","form_type":"8-K","filed_at":"2022-08-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Fate Therapeutics Q2 2022 revenue $18.5M; cash $580.8M; FT516 RMAT meeting set","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2022 collaboration revenue $18.5M from Janssen and ONO; R&D expense $81.3M, G&A $20.4M; cash $580.8M at June 30.","FT516 RMAT meeting with FDA scheduled for 3Q22 to discuss registrational pathways for relapsed/refractory aggressive B-cell lymphoma.","First patient dosed with FT536 CAR MICA/B NK cell product candidate for advanced solid tumors; multi-dose enrollment ongoing.","Janssen exercised commercial option for first iPSC-derived CAR NK collaboration program; first IND planned 2H22.","Expanded ONO collaboration: second solid tumor antigen program added, both CAR NK and CAR T candidates in development."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":36963000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":292435334.5356962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":369055,"accession_number":"0000950170-22-012381","cik":1434316,"company_name":"FATE THERAPEUTICS INC","ticker":"FATE","form_type":"8-K","filed_at":"2022-06-30T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Fate expands solid-tumor collaboration with Ono to include CAR NK cells, second target","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Ono contributes novel binding domains for a second solid tumor antigen; partnership now includes CAR NK and CAR T-cell candidates.","Fate receives research funding through Sep 2024 and is eligible for an option exercise fee, milestones, and tiered royalties.","Fate retains global manufacturing rights and the right to co-develop and co-commercialize in the US and Europe.","First iPSC-derived CAR T-cell product candidate targeting solid tumors is advancing toward clinical development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":292435334.5356962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":369054,"accession_number":"0000950170-22-011554","cik":1434316,"company_name":"FATE THERAPEUTICS INC","ticker":"FATE","form_type":"8-K","filed_at":"2022-06-13T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Fate Therapeutics shareholders approve 2022 Stock Plan, elect all director nominees","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Stockholders approved 2022 Stock Option and Incentive Plan with 61.5M for, 23.2M against, 84.7K abstain.","Class III directors Coughlin, Wolchko, and Agarwal elected; Agarwal received 69.7M for, 15.0M withheld.","Ratification of Ernst & Young as auditor for FY2022 passed with 90.1M for, 69K against.","Non-binding advisory vote on executive compensation passed with 75.4M for, 9.1M against.","Broker non-votes of 5.5M shares on director election, say-on-pay, and plan approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":292435334.5356962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":369053,"accession_number":"0000950170-22-007377","cik":1434316,"company_name":"FATE THERAPEUTICS INC","ticker":"FATE","form_type":"8-K","filed_at":"2022-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Fate Therapeutics Q1 cash $641.7M, rev $18.4M; FT596+R-CHOP IND, FT536 solid tumor on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2022 revenue of $18.4M from Janssen/Ono collaborations; R&D expense $72.1M, G&A $20.7M.","Cash, equivalents and investments $641.7M as of March 31, 2022.","FT596+R-CHOP clinical protocol for first-line aggressive lymphoma to be submitted to FDA in 2Q22.","FT536 CAR MICA/B NK cell product candidate on track for first patient treatment in 2Q22.","Third IND candidate nominated under Janssen collaboration triggering preclinical milestone payment."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":18414000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":292435334.5356962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":388278,"accession_number":"0000950170-22-002285","cik":1434316,"company_name":"FATE THERAPEUTICS INC","ticker":"FATE","form_type":"8-K","filed_at":"2022-02-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Fate Therapeutics Q4 2021 revenue $17.1M, cash $716.6M; FT596 data shows 69% ORR, FT516 gets RMAT","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2021 revenue $17.1M from collaborations; R&D expenses $69.5M (incl. $9.4M stock comp).","Cash position $716.6M at Dec 31, 2021; FY2022 GAAP loss from ops guided $335-365M; cash use $290-315M; year-end cash >$400M.","FT596+R single-dose cohorts (≥90M cells, n=16): 69% ORR, 56% CR; no ICANS or GVHD.","FDA granted RMAT designation for FT516 in r/r DLBCL; expansion cohorts enrolling at 900M cells/dose.","Initial FT819 dose cohort cleared with no DLTs; Janssen collaboration triggered milestone for second CAR NK candidate."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":55846000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":292435334.5356962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":406210,"accession_number":"0001193125-21-356947","cik":1434316,"company_name":"FATE THERAPEUTICS INC","ticker":"FATE","form_type":"8-K","filed_at":"2021-12-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Fate Therapeutics reports positive FT516 and FT596 Phase 1 data; FT516 gets RMAT designation for DLBCL","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FT516: 6 of 10 CAR T-naive patients in ongoing response at median 9.1 months; 3 of 8 prior CAR T patients achieve CR.","FDA granted RMAT designation for FT516 in relapsed/refractory DLBCL; dose expansion at 900M cells/dose initiated.","FT596: 5 of 6 patients achieve objective response (4 CR) with single dose at 900M cells in combination with rituximab.","FT596: 10 of 11 patients treated with second cycle continue in ongoing response; 3 in CR ≥6 months. No ICANS or GvHD observed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":292435334.5356962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":406209,"accession_number":"0001193125-21-320325","cik":1434316,"company_name":"FATE THERAPEUTICS INC","ticker":"FATE","form_type":"8-K","filed_at":"2021-11-04T23:59:59+00:00","items":["1.01","1.02","9.01"],"status":"ready","headline":"Fate Therapeutics files $350M ATM equity offering with Jefferies; terminates prior Leerink facility","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed universal shelf registration on Form S-3ASR for common stock, preferred stock, debt securities, warrants, and units.","Entered Open Market Sale Agreement with Jefferies to sell up to $350M of common stock in at-the-market offerings.","Jefferies will receive a 3% commission on gross proceeds; company not obligated to sell any shares.","Terminated prior at-the-market sales agreement dated November 21, 2018 with Leerink Partners effective upon filing.","Either party may suspend or terminate the offering upon notice subject to conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":292435334.5356962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":406208,"accession_number":"0000950170-21-003055","cik":1434316,"company_name":"FATE THERAPEUTICS INC","ticker":"FATE","form_type":"8-K","filed_at":"2021-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Fate Therapeutics Q3 cash $803.6M; FT596/FT516 show 71% and 73% ORR in lymphoma Ph1","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents and investments $803.6M at Sept 30, 2021; revenue $14.2M from collaborations.","FT596 in r/r BCL: 71% ORR, 50% CR in single-dose cohorts; no ICANS or GVHD, two low-grade CRS events.","FT516 in r/r BCL: 73% ORR, 55% CR in multi-dose cohorts; 63% responders ongoing at median 5.2 months.","FT819 (iPSC-derived CAR T) first patients dosed; FT576 Ph1 enrollment initiated for multiple myeloma.","R&D expenses $53.1M, G&A $15.7M; shares outstanding 95.4M common, 2.8M preferred (convertible 5:1)."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":38777000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":292435334.5356962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":425219,"accession_number":"0001564590-21-040793","cik":1434316,"company_name":"FATE THERAPEUTICS INC","ticker":"FATE","form_type":"8-K","filed_at":"2021-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Fate Therapeutics reports Q2 2021 results; first patient dosed with FT819 iPSC CAR T-cell therapy","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2021 revenue $13.4M from collaborations; R&D expenses $48.0M; cash & investments $845.1M.","First patient treated in Phase 1 trial of FT819, first-ever iPSC-derived CAR T-cell therapy, for ALL.","FT516 interim data at ASCO: 8/11 patients (73%) objective response, 6 complete responses in B-cell lymphoma.","FT538 Phase 1 in AML: 2 patients evaluable, 1 achieved CRi; dose escalation ongoing.","Appointed Dr. Mark Plavsic as Chief Technical Officer and Dr. Yuan Xu to Board of Directors."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":24552000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":292435334.5356962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":425218,"accession_number":"0001193125-21-235830","cik":1434316,"company_name":"FATE THERAPEUTICS INC","ticker":"FATE","form_type":"8-K","filed_at":"2021-08-04T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Fate Therapeutics appoints Yuan Xu, Ph.D. to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded from 9 to 10 directors; Yuan Xu appointed as Class II director effective August 3, 2021.","Dr. Xu granted option to purchase 7,501 shares and RSUs for 4,744 shares, vesting over 3 years.","Dr. Xu previously CEO of Legend Biotech, led cilta-cel development and partnership with Janssen.","Over 25 years biopharma experience including senior roles at Merck, Gilead, and Novartis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":292435334.5356962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}